Department of Nuclear Medicine, LMU Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3662-3679. doi: 10.1007/s00259-024-06783-x. Epub 2024 Jun 20.
To provide practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands.
This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO).
Positron emission tomography (PET) using somatostatin receptor (SSTR) ligands can detect meningioma tissue with high sensitivity and specificity and may provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. SSTR-directed PET imaging can be particularly useful for differential diagnosis, delineation of meningioma extent, detection of osseous involvement, and the differentiation between posttherapeutic scar tissue and tumour recurrence. Moreover, SSTR-peptide receptor radionuclide therapy (PRRT) is an emerging investigational treatment approach for meningioma.
These practice guidelines will define procedure standards for the application of PET imaging in patients with meningiomas and related SSTR-targeted PRRTs in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers, facilitate comparability of studies, and to collect larger databases. The current document provides additional information to the evidence-based recommendations from the PET/RANO Working Group regarding the utilization of PET imaging in meningiomas Galldiks (Neuro Oncol. 2017;19(12):1576-87). The information provided should be considered in the context of local conditions and regulations.
提供使用放射性标记生长抑素受体(SSTR)配体诊断和治疗(治疗学)脑膜瘤的实践指南/程序标准。
本联合实践指南/程序标准由欧洲核医学协会(EANM)、核医学与分子成像学会(SNMMI)、欧洲神经肿瘤学协会(EANO)以及神经肿瘤学反应评估工作组的正电子发射断层扫描(PET)工作组共同制定。
使用生长抑素受体(SSTR)配体的正电子发射断层扫描(PET)可以高度敏感和特异性地检测脑膜瘤组织,并可能提供超出单独使用结构磁共振成像(MRI)或计算机断层扫描(CT)成像获得的临床相关信息。SSTR 导向的 PET 成像对于鉴别诊断、脑膜瘤范围的划定、骨受累的检测以及治疗后瘢痕组织与肿瘤复发的鉴别特别有用。此外,SSTR-肽受体放射性核素治疗(PRRT)是脑膜瘤的一种新兴研究治疗方法。
这些实践指南将为脑膜瘤患者 PET 成像的应用以及常规实践和临床试验中的相关 SSTR 靶向 PRRT 制定程序标准,并有助于协调各中心的数据采集和解释,促进研究的可比性,并收集更大的数据库。本文件提供了关于在脑膜瘤中使用 PET 成像的 PET/RANO 工作组基于证据的建议的补充信息(Neuro Oncol. 2017;19(12):1576-87)。提供的信息应结合当地条件和规定进行考虑。